Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zibotentan in Prostate Cancer with Bone Metastases
NCT00090363Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2004
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of zibotentan in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Time to Progression at 2 years. Started Jul 2004; status: completed.
02
Drugs
zibotentan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00090363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090363.